Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...
One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...
The trial enrolled 751 adults with obesity or overweight conditions and at least one weight-related medical problem ...
The U.K. will soon offer Eli Lilly's Mounjaro for people with obesity — but only to a small share of those medically eligible ...
Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.